Nephro Care India Q2 Results 2026: PAT ₹3 Cr +7%, Revenue ₹33 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹33Cr
- +51.4% YoY
- +14.1% QoQ
- Net profit
- ₹3Cr
- +6.6% YoY
- +71.4% QoQ
- Margin
- 14.53%
- −2.8 pp YoY
- +2.1 pp QoQ
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Nephro Care India Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Quarter ended 30 September 2026:. Quarterly Figures for Q2 September 2026 (Standalone):.
From Nephro Care India Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Nephro Care India's revenue grow in the September 2026 quarter?
- Quarter ended 30 September 2026:
- Income from IPD Services: ₹1,915.45 Lakhs
- Income from OPD Services: ₹836.60 Lakhs
- Income from sale of medicines from pharmacy: ₹578.07 Lakhs
- Total net sales: ₹3,330.12 Lakhs
- Profit/Loss after tax: ₹276.22 Lakhs
- Quarter ended 30 September 2025 (Year-on-Year comparison):
- Income from IPD Services: ₹1,122.17 Lakhs
- Income from OPD Services: ₹624.12 Lakhs
- Income from sale of medicines from pharmacy: ₹465.42 Lakhs
- Total net sales: ₹2,211.71 Lakhs
- Profit/Loss after tax: ₹160.79 Lakhs
2 more points from Nephro Care India Ltd's call on revenue
Create a free account to keep reading this call
What happened to Nephro Care India's margins in Q2 FY27?
Quarterly Figures for Q2 September 2026 (Standalone):
Locked: what Nephro Care India Ltd said on margins
Also locked on this page: capex, fundraising
Free account, 30 seconds. No card needed.
What capex is Nephro Care India planning?
See what Nephro Care India Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Nephro Care India raising money or cutting debt?
Cash flow statements (pages 7 and 14) show no proceeds from borrowings or repayment of borrowings under…
Locked: what Nephro Care India Ltd said on fundraising
Also locked on this page: margins, capex
Free account, 30 seconds. No card needed.
How big is Nephro Care India's order book?
Nephro Care India Ltd — Quarterly revenue & net profit
Nephro Care India Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 33 | 22 | +51.4% | 29 | +14.1% |
| Operating profit (EBITDA) | 5 | 4 | +27.4% | 4 | +33.7% |
| Operating margin | 14.53% | 17.28% | -2.8 pp | 12.4% | +2.1 pp |
| Profit before tax | 4 | 3 | +5% | 3 | +37.4% |
| Net profit (PAT) | 3 | 3 | +6.6% | 2 | +71.4% |
| EPS (₹) | 1.67 | 1.57 | +6.4% | 0.98 | +70.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹33 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Healthcare Services
Continue your research
Others in Healthcare Services this season
- Manipal Health (Q2 FY27)
Revenue from operations for Q2 FY27: INR 3,399 crore, up 37.3% year-on-year (vs INR 2,475 crore in Q2 FY26). Key investor presentation takeaways from Manipal He
- Park Medi World (Q2 FY27)
other income) was ₹5,110 mn, a 25% YoY increase from ₹4,102 mn in Q2 FY’26. Key investor presentation takeaways from Park Medi World Ltd's Q2 FY27 investor pres
- Gaudium IVF (Q2 FY27)
Revenue from operations for quarter ended September 30, 2026: ₹3,741.11 lakhs (Consolidated), ₹2,805.68 lakhs (Standalone) . Key results statement takeaways fro
- Lotus Eye Hospit (Q2 FY27)
1,303.84 lakhs for the quarter ended September 30, 2025, indicating a year-on-year increase of approximately 36%. Key results statement takeaways from Lotus Eye
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nephro Care India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nephro Care India Ltd Q2 FY27 results?
Quarter ended 30 September 2026:. Quarterly Figures for Q2 September 2026 (Standalone):.
What is Nephro Care India Ltd share price analysis?
Nephro Care India Ltd currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of ₹130 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Nephro Care India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.